Using Recursive Logistic Regression to Develop a Patient-Reported Outcome in Non-Cystic Fibrosis Bronchiectasis

ORSNZ+NZSA Joint Conference, Christchurch, November 2015

Mark C. Wheldon\textsuperscript{1,2}, Alain C. Vandal\textsuperscript{1,3}, Anne-Cécile Bourien\textsuperscript{4}, Lata Jayaram\textsuperscript{5}, Noel Karalus\textsuperscript{6}, Cecilia Tong\textsuperscript{2}, Hans Hockey\textsuperscript{7}, and Conroy Wong\textsuperscript{3}

\textsuperscript{1}Auckland University of Technology, \textsuperscript{2}Middlemore Clinical Trials, \textsuperscript{3}Counties Manukau Health, \textsuperscript{4}ENSAI France, \textsuperscript{5}Monash Health Sleep Lab, \textsuperscript{6}Waikato District Health Board, \textsuperscript{7}Biometrics Matters Ltd.
EMBRACE Trial


Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

Conroy Wong, Lata Jayaram, Noel Karalus, Tam Eaton, Cecilia Tong, Hans Hockey, David Milne, Wendy Fergusson, Christine Tuffery, Paul Sexton, Louanne Storey, Toni Ashton

Summary

Background Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis.

Methods We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratified by centre. Participants, research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV1) before bronchodilation, and change in total score on St George's respiratory questionnaire (SGRQ). Analyses were by intention to treat. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493.

Findings 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations was 0.59 per patient in the azithromycin group and 1.57 per patient in the placebo group in the 6-month treatment period (rate ratio 0.38, 95% CI 0.26–0.54; p<0.0001). Prebronchodilator FEV1 did not change from baseline in the
Bronchiectasis

- Respiratory condition.
- Caused by chronic infection of airways.
- Signs and symptoms:
  - chronic inflammation of airways
  - bacterial infection
  - recurring exacerbations
  - increased mortality.
  - disabling cough
  - production of large quantities of sputum
  - reduced quality of life.
EMBRACE Design

Objectives
Assess the effect of azithromycin on health-related quality of life and lung function in patients 18–80 years with bronchiectasis (diagnosed by CT scan).

Design
Multicenter (3), double-blind, placebo-controlled, parallel group (1:1), 141 pts total.

Intervention
500mg azithromycin capsule vs. placebo, 3 days per week, for 6 months.

Follow-up
6 months (treatment period) and 12 months.

1° Endpoints
i) Rate of Event Based Exacerbations (EBEs) over 6 mo. treatment period;
   ii) Change in St. George’s Respiratory Questionnaire (tot. score); (+ others).

2° Endpoints
Symptom scores for: sputum purulence, sputum volume, dyspnoea; (+ others).
Exacerbations

- Exacerbations and symptom scores recorded prospectively in patient diaries.
- Each patient-day judged *exacerbation or no exacerbation*.
- Key symptoms of an exacerbation are
  - Sputum volume
  - Sputum purulence (colour)
  - Dyspnoea (shortness of breath, coughing).
- Two types: Event-based (EBE) and Symptom-based (SBE).
Figure: Diarized days by Event-based exacerbations status for each EMBRACE location, all patient-days.
Exacerbations

EBE is Physician-Determined

➤ EBEs require treatment with antibiotics.
➤ Ascertainment of EBE requires contact with clinician.

SBE is Patient-Determined

➤ SBEs are adjudicated using daily symptom diaries completed by patients.
➤ Patients have input into evaluation of their own health status.
➤ This is a patient-reported outcome.
Manually Adjudicated SBEs (manSBEs)

- Adjudication of SBEs originally done by manual review of diaries.
- This was laborious and time-consuming.
- Eventually abandoned.
Goals

Automatically Adjudicate SBEs

- Automatically adjudicate SBEs.
- In the process, revisit the definition \( \Rightarrow \) New SBE.

Validate New SBE Against EBE

- Estimate performance of new SBE as a predictor of EBE.
- Assess treatment sensitivity of new SBE.
Jointly Validate Against Patient-Reported Wellbeing

- Patients also reported their general wellbeing in the diaries.
- Assess, and improve, performance of new SBE as a measure of wellbeing.
Method

Data

- Observed \(\sim 50,000\) patient-days observed on 141 patients across 3 centres over 6 months.

- **Symptoms**: patients rated severity of
  - Sputum purulence, sputum volume, dyspnoea on a validated 5-point scale, 0 “no symptom” \(\rightarrow\) 4 “very much”.

- **Wellbeing**: “I feel well”, 1 “strongly agree” \(\rightarrow\) 5 “strongly disagree”.

Method

Data

- **Observed**: ~ 50,000 patient-days observed on 141 patients across 3 centres over 6 months.

- **Symptoms**: patients rated severity of
  - Sputum purulence, sputum volume, dyspnoea on a validated 5-point scale, 0 “no symptom” → 4 “very much”.

- **Wellbeing**: “I feel well”, 1 “strongly agree” → 5 “strongly disagree”.

<table>
<thead>
<tr>
<th>Table: Example data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms</strong></td>
</tr>
<tr>
<td>Pat.</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Adjudicated
Goal is a Model for Prediction

- Statistical goal is a model to predict a time-ordered, clustered, binary outcome, $\text{EBE}_{i,t}$.
- $\Rightarrow$ propose a model (somehow!).
- Verify it has good predictive power.
Model Selection

- Based on manSBE procedure, decided to use symptom scores and EBE at an earlier time-point (\(\text{EBE}_{i,t-\delta}, 0 < \delta\)) as explanatory variables.

- Used a GLMM, logit link, with random intercepts for patient.

\[
\text{EBE}_{i,t} \sim \text{Bern}(p_{i,t})
\]

\[
\logit p_{i,t} | (x, b_i) = x'_{i,t} \beta + b_i
\]

\[
b_i \sim \text{Normal}(0, \tau^2)
\]

- \(x_{i,t}\) contains symptom scores averaged over two time windows (contemporaneous, earlier), and \(\text{EBE}_{i,t-\delta}\):

\[
x'_{i,t} = \begin{bmatrix} 1 & \overline{SV}_{i,\text{cont.}} & \overline{SP}_{i,\text{cont.}} & \overline{DY}_{i,\text{cont.}} \\ \overline{SV}_{i,\text{earl.}} & \overline{SP}_{i,\text{earl.}} & \overline{DY}_{i,\text{earl.}} & \text{EBE}_{i,t-\delta} \end{bmatrix}
\]
Model Selection

- Dichotomize using a threshold, $c$, such that sensitivity $=$ specificity:

$$SBE \equiv \widehat{EBE}_{i,t} = \begin{cases} 
1 & \text{if } \hat{p}_{i,t} > c \\
0 & \text{if } \hat{p}_{i,t} \leq c 
\end{cases}$$

Design parameters are: $x$, $\delta$, $c$.

$x$, $\delta$ Time windows, averaging method, EBE offset chosen to give good in-sample predictive performance (using AUC).

$\delta = 5$

$c$ Two-stage estimation of $c$. 

Method Models for Prediction
Model Performance

Two-fold Cross-validation

- Split data into a training set and a hold-out set for validation.
- Randomly select 70 percent of the patients and allocate all their observations to the training set.
- The remainder go into the hold-out set.
Prospective Prediction

▶ The selected model is retrospective in that today’s prediction depends on earlier GP-adjudicated EBEs.

\[
\text{logit } p_{i,t} \mid (EBE_{i,t-5}, \cdot) = x_i' \beta + b_i
\]  

(1)

▶ We want a prospective model based on patient-reported outcomes ⇒ must use its own earlier predictions.

\[
\text{logit } p_{i,t} \mid (\widehat{EBE}_{i,t-5}, \cdot) = z_i' \beta + b_i
\]  

(2)

▶ (1) is a recursive logistic model (Bonney, 1986, 1987).
▶ To fit (2), a sequential procedure was used.
Sequential Approach

1. Initialize by generating retrospective predictions, \( \widehat{EBE}_{i,1}^{[ret]}, \ldots, \widehat{EBE}_{i,5}^{[ret]} \), using \( \widehat{\beta} \) and threshold, \( c^{[ret]} \), from the retrospective model.

Using the training set:

2. Sequentially generate prospective predictions \( \widehat{EBE}_{i,6}^{[pro]}, \widehat{EBE}_{i,7}^{[pro]}, \ldots \).
   - Use “population level” predictions
   - Use \( c^{[ret]} \) to threshold the predicted probabilities (we have to because this is the only \( c \) currently available).

3. Re-estimate the binary threshold \( \rightarrow c^{[pro]} \).

Using the hold-out set:

4. Repeat 2 using \( c^{[pro]} \).
Method Overview

1. Build a **retrospective** prediction model for $\text{EBE}_t$ using
   - symptom scores
   - GP-adjudicated EBE status at times $t \in [t - \delta, t_0)$.

2. Convert to a “prospective” model for $\text{EBE}_t$ using
   - retrospective design
   - patient-report-derived EBE status at times $t \in [t - \delta, t_0)$.

### Results

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Model</th>
<th>$c$ (used)</th>
<th>$c$ (Opt.)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training</td>
<td>Retro.</td>
<td>0.093</td>
<td>0.093</td>
<td>90</td>
<td>92</td>
</tr>
</tbody>
</table>

Our prospective SBE predictor misses 10 percent of the EBEs (1 in 10) and calls an EBE 21 percent of the time there isn’t one (1 in 5). Relative to using the whole dataset, estimated sensitivity equals, and specificity is 86 percent (↓ 13 percentage points).
## Results

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Model</th>
<th>$c$ (used)</th>
<th>$c$ (Opt.)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training</td>
<td>Retro.</td>
<td>0.093</td>
<td>0.093</td>
<td>90</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Prosp.</td>
<td>0.093</td>
<td>0.048</td>
<td>76</td>
<td>88</td>
</tr>
</tbody>
</table>

Our prospective SBE predictor misses 10 percent of the EBEs (1 in 10) and calls an EBE 21 percent of the time there isn’t one (1 in 5). Relative to using the whole dataset, Estimated sensitivity equal, Specificity is 86 percent (↓13 percentage points).
### Results

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Model</th>
<th>$c$ (used)</th>
<th>$c$ (Opt.)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training</td>
<td>Retro.</td>
<td>0.093</td>
<td>0.093</td>
<td>90</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Prosp.</td>
<td>0.093</td>
<td>0.048</td>
<td>76</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Prosp.</td>
<td>0.048</td>
<td>0.048</td>
<td>83</td>
<td>83</td>
</tr>
</tbody>
</table>

Our prospective SBE predictor misses 10 percent of the EBEs (1 in 10) and calls an EBE 21 percent of time there isn’t one (1 in 5). Relative to using the whole dataset, estimated sensitivity equal, specificity is 86 percent (↓ 13 percentage points).
## Results

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Model</th>
<th>$c$ (used)</th>
<th>$c$ (Opt.)</th>
<th>Sens. (%)</th>
<th>Spec. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training</td>
<td>Retro.</td>
<td>0.093</td>
<td>0.093</td>
<td>90</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Prosp.</td>
<td>0.093</td>
<td>0.048</td>
<td>76</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td>Prosp.</td>
<td>0.048</td>
<td>0.048</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>Hold-out</td>
<td>Prosp.</td>
<td>0.048</td>
<td>—</td>
<td>90</td>
<td>79</td>
</tr>
</tbody>
</table>

- Our prospective SBE predictor,
  - misses 10 percent of the EBEs (1 in 10)
  - calls an EBE 21 percent of time there isn’t one (1 in 5).

- Relative to using the whole dataset,
  - Estimated sensitivity equal,
  - Specificity is 86 percent (↓ 13 percentage points).
Patients also reported wellbeing each day using a 1–5 scale.

Ultimately, we’re interested in a patient-reported outcome that is sensitive to both changes in physical state and patient-reported wellbeing.

How is our new definition of SBE associated with wellbeing?

Do we get “closer” to wellbeing with SBE rel. to EBE?
Wellbeing and SBE

Linear predictor, WB, EBE
Subject Number=101

Figure: Wellbeing and SBE linear predictor for patient no. 101.
Wellbeing and SBE

Linear predictor, WB, EBE
Subject Number=147

Figure: Wellbeing and SBE linear predictor for patient no. 147.
Wellbeing and SBE

- Weighted Pearson correlation between wellbeing and the linear predictor from the SBE model is $\hat{\rho} = 0.33$.
- Future: combine the SBE prediction model with a similar one for wellbeing.
Exacerbations are an outcome of interest in the study of bronchiectasis.

Ascertainment of event-based exacerbations (EBEs) requires clinical assessment.

Symptom-based exacerbations (SBEs) are ascertained from patient-reported symptom scores and exacerbation history, coded “by hand”.

We used logistic regression to develop an “automatic” coding scheme; changes in symptoms that are associated with changes in physical state (EBE).

As a classifier of EBE the performance was quite good (sens. 90%, spec. 79%).
